Clinical trials list

Clinical trials list

Active Trials – Recruiting or in Study Start-Up

The following ALTG trials are recruiting or in the study start-up stage.

Trial  Number Title StatusMore Information
ILLUMINATEPhase II, single arm trial to assess the efficacy and tolerability for patients with the use of Durvalumab and Tremelimumab with Chemotherapy in metastatic EGFR non-small cell lung cancer (NSCLC) following progression on EGFR tyrosine kinase inhibitors. RecruitingTrial summary
ANZCTR
PEARL
ALTG 13/008
Efficacy of early referral to palliative care for improving quality of life and health care resources following recent diagnosis of advanced thoracic malignancies.RecruitingTrial Summary
ANZCTR
ALKTERNATE
ALTG 16/007
Single arm phase 2 trial in ALK-rearranged NSCLC alTERNATing lorlatinib with crizotinib after progression on first line crizotinib
RecruitingANZCTR
DREAM3R /ALTG 18/001DREAM3R: DuRvalumab (MEDI4736) with chEmotherapy as first line treAtment in advanced pleural Mesothelioma - A phase 3 Randomised trialIn Development

Trials In Follow Up (closed to recruitment)

Trial Number TitleStatusMore Information
OSCILLATE
ALTG 16/005
Phase 2 trial of alternating osimertinib with gefitinib in patients with EGFR-T790M mutation positive advanced non-small cell lung cancerClosed to recruitmentTrial Summary
ANZCTR
BR.31
ALTG 14/001
A phase III prospective double-blind placebo-controlled randomized study of adjuvant MEDI4736 in completely resected non-small cell lung cancerClosed to recruitmentTrial Summary
ANZCTR
clinicaltrials.gov
DREAM
ALTG 15/003
A phase 2 trial of durvalumab with first line chemotherapy in mesothelioma with a safety run inClosed to recruitmentANZCTR
clinicaltrials.gov
NIVORAD
ALTG 14/002
A randomised phase 2 trial of nivolumab and stereotactic ablative body radiotherapy in advanced non-small cell lung cancer progressing after first or second line chemotherapyClosed to recruitmentTrial Summary
ANZCTR
STIMULI
ALTG 16/012
Phase II trial to assess the overall survival benefit for patients with the use of Nivolumab and Ipilimumab in limited-stage small cell lung cancer (SCLC) after chemo-radiotherapy Closed to recruitmentTrial Summary
ANZCTR
clinicaltrials.gov
BR.34
ALTG 15/004
A Randomized Trial of Durvalumab and Tremelimumab +/- Platinum-Based Chemotherapy in Patients With High-Risk, Metastatic (Stage IV) Squamous or Non-Squamous Non-Small Cell Lung Cancer (NSCLC)Closed to recruitmentTrial Summary
ANZCTR
clinicaltrials.gov
CHISEL
ALTG 09/005
TROG 09.02
A Randomised Phase III Trial of Highly Conformal Hypofractionated Image Guided ("Stereotactic") Radiotherapy (HypoRT) Versus Conventionally Fractionated Radiotherapy (ConRT) for Inoperable Early Stage I Non-small Cell Lung Cancer (CHISEL)Closed to recruitment ANZCTR
clinicaltrials.gov

Cobadged/ Endorsed Trials

The following trials have been endorsed by the ALTG.

Trial Number Title StatusMore Information
ANZ LCNF
ALTG 16/013
Activities and influence of the specialist lung cancer nurseIn development
CORE
ALTG 16/011
TROG 16.03
Conventional Care Versus Radioablation (Stereotactic Body Radiotherapy) for Extracranial Oligometastases (CORE)Closed to recruitmentclinicaltrials.gov
HQOL in MM
ALTG 13/002
Health Related Quality of Life in Malignant MesotheliomaCompletedANZCTR
OPAL
ALTG 13/004
Do lung cancer patients who receive telephone or on-line support have better wellbeing outcomes than those who receive a booklet only.CompletedANZCTR
P_LUNG GP
ALTG 10/001
TROG 11.03
Randomised phase 3 trial of high dose palliative radiotherapy (HDPRT) vs concurrent chemotherapy and HDPRT (C-HDPRT) in patients with good performance status, locally advanced/ small volume metastatic NSCLC not suitable for radical chemo-radiotherapyClosed to follow upANZCTR
Rekindle
ALTG 13/003
Testing an online resource to promote sexual wellbeing for both patients and their partnersCompletedANZCTR
SABR-OS
ALTG 15/001
TROG 13.03
A randomised phase 2 trial to test the feasibility of randomising patients with peripheral stage I NSCLC to either Stereotactic Ablative Radiotherapy (SABR) Or SurgeryIn development
SAFRON II
ALTG 13/001
TROG 13.01
Stereotactic Ablative Fractionated Radiotherapy versus Radiosurgery for Oligometastatic Neoplasia to the lung: a randomised phase 2 trialClosed to recruitment
ANZCTR
OUTRUN
TROG 17.02
A Randomised Phase II Trial of Osimertinib With or Without SRS for EGFR Mutated NSCLC With Brain MetastasesOpen to recruitmentANZCTR

Completed/Closed Trials

Trial  Number Title Publications
SCRIBE
ALTG 16/004
A phase 2 study of nivolumab with radiotherapy or nivolumab with ipilimumab in the treatment of small cell lung cancer brain metastasesTerminated. Funding withdrawn.
PA in Lung (PAL)
ALTG 08/001
Physical Activity in Lung cancer patientsAnnals of Oncology, Vol 28, Issue 8, Pages 1889-1897, August 2017
CUMM
ATLG 12/003
Chemotherapy Utilisation for Malignant MesotheliomaAsia-Pacific Journal of Clinical Oncology, Vol 11, Issue 1, Pages 85–92, March 2015
ALTG 04/001Randomized comparison of first line docetaxel/gemcitabine doublet chemotherapy versus sequential single agent chemotherapyLung Cancer, Vol 49, Supplement 2, Pages S263, July 2005
MATES
ALTG 04/003
Maintenance Thalidomide in Mesothelioma PatientsThe Lancet Oncology, Vol 14, No. 6, Pages 543–551, May 2013
PACT
ALTG 04/009
Lung Cancer Patient PreferencesLung Cancer, Vol 95, Pages 8-14, May 2016
NITRO
ALTG 06/003
A randomised, phase III trial of adding nitroglycernin to first line chemotherapy in advanced non-small cell lung cancer.Annals of Oncology, Vol 26, Pages 2280-2286, September 2015
BR29
ALTG 09/001
Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancerEuropean Journal of Cancer, Vol 50, Issue 4, Pages 706 - 712, March 2014
BR26
ALTG 09/002
Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancerThe Lancet Oncology, Vol 15, No. 12, Pages 1379-1388, Nov 2014
B2P2M2
ALTG 09/004
A phase II clinical trial of the Vascular Disrupting Agent BNC105P as second line chemotherapy for advanced Malignant Pleural MesotheliomaLung Cancer, Vol 81, Pages 422-427, May 2013
ALTG 10/002A Pilot Study To Develop A Classification Algorithm For Identifying Patients With Adenocarcinoma Of Lung Suitable For Individualized TherapiesStudy completed late 2011
ALTG 10/003Implementing standardised PET procedures for scanning, data collection and reporting in patients with NSCLC across Australia’s ALTG sites: A feasibility study.Study completed late 2011
ALTG 10/004Limiting the functional decline of patients with advanced non-small cell lung cancer.Journal of Thoracic Oncology Vol 7, Issue 9, July 2011
Surveillance in patients with MPM
ALTG 17/001
A prospective single arm phase II trialTerminated. Funding withdrawn.